A citation-based method for searching scientific literature

Yves Pommier, Mark J O'Connor, Johann de Bono. Sci Transl Med 2016
Times Cited: 283

Arnab Ray Chaudhuri, Elsa Callen, Xia Ding, Ewa Gogola, Alexandra A Duarte, Ji-Eun Lee, Nancy Wong, Vanessa Lafarga, Jennifer A Calvo, Nicholas J Panzarino, Sam John, Amanda Day, Anna Vidal Crespo, Binghui Shen, Linda M Starnes, Julian R de Ruiter, Jeremy A Daniel, Panagiotis A Konstantinopoulos, David Cortez, Sharon B Cantor, Oscar Fernandez-Capetillo, Kai Ge, Jos Jonkers, Sven Rottenberg, Shyam K Sharan, André Nussenzweig. Nature 2016
Times Cited: 383

List of shared articles

Times cited

Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
Dae-Seok Kim, Cristel V Camacho, W Lee Kraus. Exp Mol Med 2021

Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51.
Gwenola Manic, Martina Musella, Francesca Corradi, Antonella Sistigu, Sara Vitale, Sara Soliman Abdel Rehim, Luca Mattiello, Eva Malacaria, Claudia Galassi, Michele Signore,[...]. Cell Death Differ 2021

Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.
M Chiappa, F Guffanti, F Bertoni, I Colombo, G Damia. Drug Resist Updat 2021

Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies.
Colin Stok, Yannick P Kok, Nathalie van den Tempel, Marcel A T M van Vugt. Nucleic Acids Res 2021

CRISPR Screens in Synthetic Lethality and Combinatorial Therapies for Cancer.
Laia Castells-Roca, Eudald Tejero, Benjamín Rodríguez-Santiago, Jordi Surrallés. Cancers (Basel) 2021

Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi Resistance.
Christina Andronikou, Sven Rottenberg. Trends Mol Med 2021

Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.
Ke Cong, Min Peng, Arne Nedergaard Kousholt, Wei Ting C Lee, Silviana Lee, Sumeet Nayak, John Krais, Pamela S VanderVere-Carozza, Katherine S Pawelczak, Jennifer Calvo,[...]. Mol Cell 2021

Understanding and overcoming resistance to PARP inhibitors in cancer therapy.
Mariana Paes Dias, Sarah C Moser, Shridar Ganesan, Jos Jonkers. Nat Rev Clin Oncol 2021

Tackling PARP inhibitor resistance.
Kasper Fugger, Graeme Hewitt, Stephen C West, Simon J Boulton. Trends Cancer 2021

Determinants of Homologous Recombination Deficiency in Pancreatic Cancer.
Max M Wattenberg, Kim A Reiss. Cancers (Basel) 2021

Targeting DNA repair in cancer: current state and novel approaches.
Apostolos Klinakis, Dimitris Karagiannis, Theodoros Rampias. Cell Mol Life Sci 2020

53BP1: a DSB escort.
Zachary Mirman, Titia de Lange. Genes Dev 2020

Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
Feiyue Zheng, Yi Zhang, Shuang Chen, Xiang Weng, Yuefeng Rao, Hongmei Fang. Biomed Pharmacother 2020

The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.
Madalena Tarsounas, Patrick Sung. Nat Rev Mol Cell Biol 2020